Enabling the efficient delivery of the future COVID-19 vaccine
TIACA’s Board member, Emir Pineda, Manager of Aviation Trade and Logistics at Miami International Airport, answers International Airport Review’s questions regarding how the development and transportation of a COVID-19 vaccine will impact the air cargo sector.
In August 2020, The International Air Cargo Association (TIACA) and Pharma.Aero announced a collaboration focused on providing global guidance for the air cargo industry to enable the optimal transportation of the expected COVID-19 vaccine.
Following this, International Airport Review spoke to Emir Pineda, Manager of Aviation Trade and Logistics at Miami International Airport (MIA) and TIACA Board member, regarding this industry development.
Why did TIACA choose Pharma.Aero for this collaboration?
It was a natural evolution after the Memorandum of Understading (MoU) that we signed with Pharma.Aero in November 2019 during our Executive Summit in Budapest.
Pharma.Aero represents an association with cross-industry collaboration among pharmaceutical manufacturers, CEIV-certified cargo communities, airport operators and other air cargo industry stakeholders dedicated to improving the logistics process for pharma shippers.
This combination and focus on pharma shippers made it an easy choice to team up based on our joint ambition to provide useful guidelines to our members to maximise their preparedness for transporting and distributing the future COVID-19 vaccines.